The role of protease activated receptors on platelets
蛋白酶激活受体对血小板的作用
基本信息
- 批准号:10579822
- 负责人:
- 金额:$ 47.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-15 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AffectAllelesAnimal ModelBinding SitesBiologicalBiophysicsBloodBlood PlateletsBlood flowCollaborationsComplexComplicationDataDevelopmentDiseaseEndotheliumGenerationsGenetic PolymorphismGoalsHealthHumanIndividualInjuryLearningLigand BindingMeta-AnalysisMicrofluidic MicrochipsMissionMolecularMulticellular ProcessMutateMutationPathologicPathway interactionsPersonsPhysiologicalProcessProteinase-Activated ReceptorsPublic HealthPulmonary EmbolismQualifyingRelative RisksResearchRisk FactorsRisk ReductionRoleSerineSignal PathwaySignal TransductionSingle Nucleotide PolymorphismStructureTestingThrombinThrombosisThrombusTranslatingUnited States National Institutes of HealthVariantVenousVenous Thrombosisantagonistdrug developmentendothelial dysfunctionexperienceextracellulargenome wide association studyin vivoin vivo Modelinhibitorinnovationinsightmouse modelmouse protease-activated receptor 4neutrophilpharmacologicplatelet functionpreventprogramsprotease-activated receptor 3protease-activated receptor 4therapeutic targetvalidation studiesvenous thromboembolism
项目摘要
PROJECT SUMMARY/ABSTRACT
Venous thrombosis (VT) and its major complication, pulmonary embolism (PE), are often grouped together and
called venous thromboembolism (VTE). VTE is a major health problem that affect nearly 600,000 people each
year. The historical drivers of VTE are blood stasis, endothelial dysfunction, and hypercoagulation (Virchow’s
triad). It is now recognized that platelets and neutrophils have a critical initiating role. The molecular mechanisms
are only being uncovered. Given that hypercoagulation is a risk factor and thrombin activated protease activated
receptor 4 (PAR4) promotes procoagulant platelets, phosphatidyl serine (PS) exposure and subsequent
thrombin generation, we propose that PAR4 is an important contributor to VTE. The long-term goals of this
research program are to uncover the mechanisms of PAR4 activation at the molecular level and test these
mechanism in vivo to inform disease processes and potential drug development. The scientific premise of this
proposal is based our preliminary data showing that extracellular loop 3 (ECL3) of PAR4 coordinates with the
ligand binding site (LBS) during PAR4 activation. Further, mutations in either ECL3 or the LBS disrupt PAR4
signaling to the same degree. This points to an essential role for ECL3 in PAR4 activation. The overall objective
of this proposal is to 1) to determine how PAR4 contributes to the initiation and propagation of venous thrombosis
using mouse models, 2) conduct proof-of-concept studies using PAR4 antagonist to treat VT, 3) to translate our
recent structural insights on the PAR4 activation mechanism to PAR4 function in vivo. We will do this by taking
advantage a PAR4 variant in human platelets and a new mouse model. Our overall hypothesis is that the
sustained signaling from PAR4 on platelets is a driver of VTE and reduced PAR4 signaling from hypo-reactive
variants or pharmacological inhibitors will lead to protection from VTE. Our innovative approach will take
advantage of a new mouse model that recreates a polymorphism in ECL3 and will allow us to determine the
mechanism of how this polymorphism contributes to platelet function and thrombosis. The completion of the
proposed studies will accomplish two major advances. 1) we will be the first to specifically examine the role of
PAR4 in venous thrombosis. 2) we will continue to push our basic understanding of PAR activation mechanisms
by testing the observations from our structural studies in vivo to determine how these mechanisms operate in
physiological and pathophysiological contexts.
项目总结/摘要
静脉血栓形成(VT)及其主要并发症肺栓塞(PE)通常被归为一类,
静脉血栓栓塞症(VTE)。静脉血栓栓塞是一个主要的健康问题,影响近60万人,
年VTE的历史驱动因素是血瘀、内皮功能障碍和高凝状态(Virchow的
三和弦)。现在认识到血小板和中性粒细胞具有关键的启动作用。的分子机制
只是被发现了。鉴于高凝是一个危险因素,凝血酶激活的蛋白酶激活
受体4(PAR 4)促进促凝血血小板、磷脂酰丝氨酸(PS)暴露和随后的血小板聚集。
凝血酶的产生,我们认为PAR 4是导致静脉血栓栓塞的重要因素。长期目标是
研究计划是在分子水平上揭示PAR 4激活的机制,并测试这些机制。
在体内的机制,告知疾病的过程和潜在的药物开发。科学的前提是
该提议基于我们的初步数据,该数据显示PAR 4的细胞外环3(ECL 3)与
配体结合位点(LBS)。此外,ECL 3或LBS中的突变破坏PAR 4
在相同的程度上发出信号。这表明ECL 3在PAR 4活化中的重要作用。总体目标
该建议的目的是:1)确定PAR 4如何促进静脉血栓形成的发生和传播
使用小鼠模型,2)使用PAR 4拮抗剂治疗VT进行概念验证研究,3)将我们的
PAR 4激活机制的最新结构见解PAR 4在体内的功能。我们将通过采取
在人血小板中的PAR 4变体和新的小鼠模型中的优势。我们的总体假设是
血小板上来自PAR 4的持续信号传导是VTE的驱动因素,而来自低反应性血小板的减少的PAR 4信号传导是VTE的驱动因素。
变体或药理学抑制剂将导致对VTE的保护。我们的创新方法将
这是一个新的小鼠模型的优势,它重建了ECL 3的多态性,并使我们能够确定
这种多态性如何有助于血小板功能和血栓形成的机制。的完成
拟议的研究将取得两项重大进展。1)我们将是第一个专门研究
静脉血栓形成中的PAR 4。2)我们将继续推进我们对PAR激活机制的基本理解
通过测试我们在体内结构研究中的观察结果,以确定这些机制在体内是如何运作的。
生理和病理生理背景。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marvin Thomas Nieman其他文献
Marvin Thomas Nieman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marvin Thomas Nieman', 18)}}的其他基金
The structural basis for PAR1 biased signaling
PAR1 偏向信号传导的结构基础
- 批准号:
10042725 - 财政年份:2020
- 资助金额:
$ 47.5万 - 项目类别:
The structural basis for PAR1 biased signaling
PAR1 偏向信号传导的结构基础
- 批准号:
10241452 - 财政年份:2020
- 资助金额:
$ 47.5万 - 项目类别:
The role of protease activated receptors on platelets.
蛋白酶激活受体对血小板的作用。
- 批准号:
8274738 - 财政年份:2010
- 资助金额:
$ 47.5万 - 项目类别:
The role of protease activated receptors on platelets.
蛋白酶激活受体对血小板的作用。
- 批准号:
8478172 - 财政年份:2010
- 资助金额:
$ 47.5万 - 项目类别:
The role of protease activated receptors on platelets
蛋白酶激活受体对血小板的作用
- 批准号:
10319016 - 财政年份:2010
- 资助金额:
$ 47.5万 - 项目类别:
The role of protease activated receptors on platelets.
蛋白酶激活受体对血小板的作用。
- 批准号:
7984232 - 财政年份:2010
- 资助金额:
$ 47.5万 - 项目类别:
The role of protease activated receptors on platelets
蛋白酶激活受体对血小板的作用
- 批准号:
9241436 - 财政年份:2010
- 资助金额:
$ 47.5万 - 项目类别:
The role of protease activated receptors on platelets
蛋白酶激活受体对血小板的作用
- 批准号:
9889979 - 财政年份:2010
- 资助金额:
$ 47.5万 - 项目类别:
The role of protease activated receptors on platelets.
蛋白酶激活受体对血小板的作用。
- 批准号:
8125073 - 财政年份:2010
- 资助金额:
$ 47.5万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 47.5万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 47.5万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 47.5万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 47.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 47.5万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 47.5万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 47.5万 - 项目类别: